Tuberculosis
Authors: Patricio Escalante
Journal: Annals of Internal Medicine (2009)

In the Clinic2 June 2009TuberculosisChristine Laine, MD, MPH, Sankey Williams, MD, Harold C. Sox, MD, and Patricio Escalante, MD, MScChristine Laine, MD, MPH, Sankey Williams, MD, Harold C. Sox, MD, and Patricio Escalante, MD, MScAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-11-200906020-01006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.One third of the world population has Mycobacterium tuberculosis infection (1). Despite recent progress in the United States, tuberculosis infection remains prevalent in immigrants, immunosuppressed persons, and other high-risk groups (3). Latent tuberculosis infection (LTBI) is the most prevalent form of tuberculosis in the United States (2). LTBI can progress to active tuberculosis disease, especially in individuals with a suppressed cell-mediated immunity. Active tuberculosis disease in immuno-suppressed patients can be difficult to diagnose and can progress to disseminated forms of tuberculosis disease associated with high mortality (4). New methods ...References1. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-86. [PMID: 10517722] Google Scholar2. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350:2060-7. [PMID: 15141044] Google Scholar3. Talbot EA, Moore M, McCray E, et al. Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA. 2000;284:2894-900. [PMID: 11147986] Google Scholar4. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266-77. [PMID: 9827281] Google Scholar5. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-84. [PMID: 18593687] Google Scholar6. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367:1328-34. [PMID: 16631911] Google Scholar7. Richeldi L, Ewer K, Losi M, et al. Early diagnosis of subclinical multidrug-resistant tuberculosis. Ann Intern Med. 2004;140:709-13. [PMID: 15126254] Google Scholar8. Scano F, Vitoria M, Burman W, et al. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis. 2008;12:1370-5. [PMID: 19017444] Google Scholar9. Ghandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. [PMID: 17084757] Google Scholar10. Horsburgh CR Jr. Primary transmission of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected persons: what does the future hold in store? [Editorial]. J Infect Dis. 2008;198:1577-8. [PMID: 19062395] Google Scholar11. Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49-55. [PMID: 16357824] Google Scholar12. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361:1168-73. [PMID: 12686038] Google Scholar13. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340-54. [PMID: 17339619] Google Scholar14. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS. 2002;16:2285-93. [PMID: 12441800] Google Scholar15. Mazurek GH, Zajdowicz MJ, Hankinson AL, et al. Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis. 2007;45:826-36. [PMID: 17806046] Google Scholar16. Nienhaus A, Schablon A, Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection-analysis of discordant results, when compared to the tuberculin skin test. PLoS ONE. 2008;3:e2665. [PMID: 18628829] Google Scholar17. Palmer CE, Edwards LB. Tuberculin test in retrospect and prospect. Arch Environ Health. 1967;15:792-808. [PMID: 6061302] Google Scholar18. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE. 2008;3:e1379. [PMID: 18167540] Google Scholar19. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177:1164-70. [PMID: 18276940] Google Scholar20. Riley RL. Aerial dissemination of pulmonary tuberculosis. Am Rev Tuberc. 1957;76:931-41. [PMID: 13488004] Google Scholar21. Houk VN, Baker JH, Sorensen K, et al. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health. 1968;16:26-35. [PMID: 5638222] Google Scholar22. Noble RC. Infectiousness of pulmonary tuberculosis. Am J Infect Control. 1981;9:6019 Google Scholar23. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1994;43:1-132. [PMID: 8602125] Google Scholar24. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62. [PMID: 12588714] Google Scholar25. Kamat SR, Dawson JJ, Devadatta S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ. 1966;34:517-32. [PMID: 5296379] Google Scholar26. Gunnels JJ, Bates JH, Swindoll H. Infectivity of sputum-positive tuberculous patients on chemotherapy. Am Rev Respir Dis. 1974;109:323-30. [PMID: 4205432] Google Scholar27. Infectious Diseases Society of America. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis. 2000;31:633-9. [PMID: 11017808] Google Scholar28. Griffiths C, Sturdy P, Brewin P, et al. Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial. Lancet. 2007;369:1528-34. [PMID: 17482983] Google Scholar29. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis (2000), Accessed at www.cdc.gov/tb/pubs/corecurr/Chapter8/Chapter_8_Administrative.htm on 12 June 2009. Google Scholar30. Moonan PK, Oppong J, Sahbazian B, et al. What is the outcome of targeted tuberculosis screening based on universal genotyping and location? Am J Respir Crit Care Med. 2006;174:599-604. [PMID: 16728707] Google Scholar31. Cohen R, Muzaffar S, Capellan J, et al. The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest. 1996;109:420-3. [PMID: 8620716] Google Scholar32. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161:1376-95. [PMID: 10764337] Google Scholar33. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999;340:367-73. [PMID: 9929528] Google Scholar34. Kramer F, Modilevsky T, Waliany AR, et al. Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Am J Med. 1990;89:451-6. [PMID: 2121030] Google Scholar35. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA. 1993;270:65-8. [PMID: 8510299] Google Scholar36. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472-7. [PMID: 12569078] Google Scholar37. Richardson NL. Evaluating provider prescribing practices for the treatment of tuberculosis in Virginia, 1995 to 1998: an assessment of educational need. J Contin Educ Health Prof. 2000;20:146-55. [PMID: 11232250] Google Scholar38. Greco S, Girardi E, Navarra A, et al. Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax. 2006;61:783-90. [PMID: 16738037] Google Scholar39. Centers for Disease Control and Prevention (CDC). Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep. 2002;51:214-5. [PMID: 11922192] Google Scholar40. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360:528-34. [PMID: 12241657] Google Scholar41. Chang KC, Leung CC, Yew WW, et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:1153-8. [PMID: 16908866] Google Scholar42. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis, 2000; Accessed at www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7_Response.htm on 12 June 2009. Google Scholar43. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis, 2000; Accessed at www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7_Adherence.htm on 12 June 2009. Google Scholar44. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996;30:919-25. [PMID: 8876848] Google Scholar45. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158-63. [PMID: 16254056] Google Scholar46. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-41. [PMID: 17255740] Google Scholar47. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR Morb Mortal Wkly Rep. 2009;58:1-198. Accessed at www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm#top on 8 May 2009. Google Scholar48. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis, 2000; Accessed at www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7_Medical_Problems.htm on 12 June 2009. Google Scholar49. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-84. [PMID: 8139628] Google Scholar50. Chaulk CP, Moore-Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-51. [PMID: 7674524] Google Scholar51. Burman WJ, Dalton CB, Cohn DL, et al. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 1997;112:63-70. [PMID: 9228359] Google Scholar52. Moore RD, Chaulk CP, Griffiths R, et al. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med. 1996;154:1013-9. [PMID: 8887600] Google Scholar53. Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet. 1998;352:1340-3. [PMID: 9802271] Google Scholar54. Walley JD, Khan MA, Newell JN, et al. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet. 2001;357:664-9. [PMID: 11247549] Google Scholar55. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2003:CD003343. [PMID: 12535470] Google Scholar56. Mushlin AI, Appel FA. Diagnosing potential noncompliance. Physicians' ability in a behavioral dimension of medical care. Arch Intern Med. 1977;137:318-321. [PMID: 843149] Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: In The Clinic: Tuberculosis Metrics Cited byMonolith-modified cellulose paper for biochemical sensing applicationsHumeral Artery Aneurysm Revealing a Rare Association between Tuberculosis and Behçet's DiseaseBilateral cavitary lesions in a chest x-rayImpact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic reviewEvaluation of EZplex MTBC/NTM Real-Time PCR kit: diagnostic accuracy and efficacy in vaccinationA scoring system to effectively evaluate central nervous system tuberculosis in patients with miliary tuberculosisSymbiosis and Pathogenicity of ActinobacteriaTuberculosis and Nontuberculous MycobacteriaA 57-year-old man with inflamed, enlarged gingivae and associated bone lossCorrection: In The Clinic: Tuberculosis 2 June 2009Volume 150, Issue 11Page: ITC6-1KeywordsAdverse reactionsDirectly observed therapyDrug therapyDrugsHIV infectionsIsoniazidPulmonary diseasesSputumTreatment guidelinesTuberculosis ePublished: 2 June 2009 Issue Published: 2 June 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...